<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6585">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01964703</url>
  </required_header>
  <id_info>
    <org_study_id>ED13024</org_study_id>
    <nct_id>NCT01964703</nct_id>
  </id_info>
  <brief_title>Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes</brief_title>
  <official_title>Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Rubus occidentalis extract could improve
      fasting or postprandial serum glucose levels, and related metabolic markers among patients
      with prediabetes (impaired fasting glucose and/or impaired glucose tolerance).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>serum glucose (fasting and post 75g oral glucose tolerance test)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum insulin</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>HOMA IR, QUICKI, HOMA beta, lipid profile, inflammatory markers</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Prediabetes (Impaired Fasting Glucose and/or Impaired Glucose Tolerance)</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rubus occidentalis extract 900mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>taking Rubus occidentalis extract 900mg/day for 12weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rubus occidentalis extract 1800mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>taking Rubus occidentalis extract 1800mg/day for 12weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rubus occidentalis extract</intervention_name>
    <arm_group_label>Rubus occidentalis extract 900mg</arm_group_label>
    <arm_group_label>Rubus occidentalis extract 1800mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 years of age or older

          -  prediabetes (fasting plasma glucose 100-125mg/dl, and/or post 75g OGTT plasma glucose
             140-199mg/dl)

        Exclusion Criteria:

          -  pregnant women

          -  taking anti-hyperglycemic agents within 3 months at the time of enrollment

          -  history of heart failure, myocardial infarction, cerebral infarction

          -  uncontrolled hypertension (systolic BP &gt; 160mmHg, or diastolic BP &gt; 100mmHg)

          -  serum triglyceride level &gt; 500mg/dl

          -  kidney dysfunction (serum Creatinine &gt; 30% of upper normal limits)

          -  hepatic dysfunction (AST, ALT &gt; 3 times of upper normal limits)

          -  taking systemic glucocorticoids within 1 month
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 14, 2013</lastchanged_date>
  <firstreceived_date>October 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Sin Gon Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
